Could Semaglutide Help People With Diabetes Quit Smoking?
Semaglutide users with type 2 diabetes had fewer medical encounters for tobacco use disorder compared to users of other diabetes drugs.
Quick Facts
What This Study Found
Among people with type 2 diabetes, semaglutide was linked to a lower risk of medical encounters related to tobacco use disorder compared to other diabetes drug classes. The effect was strongest when comparing semaglutide to insulin. It was weakest compared to other GLP-1 receptor agonists, suggesting the effect may be partly a GLP-1 class effect rather than unique to semaglutide.
Semaglutide users also had fewer prescriptions for smoking cessation medications and less counseling for smoking. These patterns held regardless of whether patients were also obese.
Key Numbers
- 20.8% pooled smoking prevalence among people with type 2 diabetes (from meta-analysis of 3.2 million people across 33 countries)
- Semaglutide linked to significantly lower risk of medical encounters for tobacco use disorder vs other drug classes
- Effect strongest vs insulin, weakest vs other GLP-1 receptor agonists
- Findings consistent regardless of obesity status
How They Did This
This was an editorial review summarizing observational data from a large retrospective database study by Wang and colleagues. It compared semaglutide users to matched users of other diabetes drug classes. No randomized controlled trial data on semaglutide and smoking cessation was available at the time of writing.
Why This Research Matters
About 21% of people with type 2 diabetes smoke, which compounds their already elevated cardiovascular risk. If semaglutide genuinely helps with smoking cessation beyond just weight and glucose control, it could offer a triple benefit: better blood sugar, weight loss, and quitting smoking. GLP-1 receptors exist in brain reward circuits, which provides a plausible mechanism.
The Bigger Picture
GLP-1 receptors exist in brain reward circuits involved in addiction. If semaglutide helps with smoking cessation, it would offer a triple benefit for diabetic smokers: better blood sugar, weight loss, and reduced tobacco use.
What This Study Doesn't Tell Us
This is an editorial commentary based on observational data, not a clinical trial. The association between semaglutide and reduced tobacco use could reflect confounding factors. People prescribed semaglutide may differ from those on insulin in ways that affect smoking behavior. No randomized evidence confirms that semaglutide directly causes smoking cessation.
Questions This Raises
- ?Is the smoking benefit specific to semaglutide or shared by all GLP-1 drugs?
- ?Does semaglutide directly reduce cravings or does weight loss indirectly help?
- ?Would a randomized trial confirm this association?
Trust & Context
- Key Stat:
- 20.8% smoking prevalence About one in five people with type 2 diabetes worldwide still smoke, compounding their cardiovascular risk
- Evidence Grade:
- Rated preliminary: this is an editorial commentary based on observational data, not a controlled trial. The association needs confirmation.
- Study Age:
- Published in 2024, commenting on recent observational data. No randomized trial yet exists for semaglutide and smoking cessation.
- Original Title:
- Semaglutide and smoking cessation in individuals with type 2 diabetes mellitus: there is no smoke without fire!
- Published In:
- Expert review of clinical pharmacology, 17(11), 1009-1012 (2024)
- Authors:
- Popovic, Djordje S(7), Patoulias, Dimitrios(10), Koufakis, Theocharis(8), Karakasis, Paschalis, Ruža, Ieva, Papanas, Nikolaos
- Database ID:
- RPEP-09081
Evidence Hierarchy
Frequently Asked Questions
Can semaglutide help you quit smoking?
Observational data suggests semaglutide users had fewer smoking-related medical visits, but this hasn't been proven in a clinical trial yet.
Why might a diabetes drug affect smoking?
GLP-1 receptors are found in brain reward circuits involved in addiction, which could explain how semaglutide might reduce tobacco cravings.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-09081APA
Popovic, Djordje S; Patoulias, Dimitrios; Koufakis, Theocharis; Karakasis, Paschalis; Ruža, Ieva; Papanas, Nikolaos. (2024). Semaglutide and smoking cessation in individuals with type 2 diabetes mellitus: there is no smoke without fire!. Expert review of clinical pharmacology, 17(11), 1009-1012. https://doi.org/10.1080/17512433.2024.2418398
MLA
Popovic, Djordje S, et al. "Semaglutide and smoking cessation in individuals with type 2 diabetes mellitus: there is no smoke without fire!." Expert review of clinical pharmacology, 2024. https://doi.org/10.1080/17512433.2024.2418398
RethinkPeptides
RethinkPeptides Research Database. "Semaglutide and smoking cessation in individuals with type 2..." RPEP-09081. Retrieved from https://rethinkpeptides.com/research/popovic-2024-semaglutide-and-smoking-cessation
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.